Selected characteristics of patients who received initial chemotherapy for first primary malignancy in adulthood, 9 SEER registries, 1975-2008
| First primary malignancy . | Total (N) . | Also received initial radiotherapy (%) . | Women (%) . | Mean age at diagnosis (y) . | Mean person-years at risk (y) . |
|---|---|---|---|---|---|
| Total* | 426 068 | 45 | 63 | 57.3 | 4.9 |
| Buccal cavity, pharynx | 9903 | 92 | 22 | 56.8 | 3.5 |
| Esophagus | 5535 | 88 | 23 | 63.1 | 2.2 |
| Stomach | 7707 | 50 | 32 | 61.3 | 2.4 |
| Colon | 38 064 | 8 | 49 | 62.5 | 4.5 |
| Rectum, rectosigmoid junction | 22 757 | 74 | 39 | 61.1 | 4.4 |
| Anus, anal canal, anorectum | 3476 | 96 | 62 | 58.6 | 5.4 |
| Biliary tract | 4015 | 36 | 41 | 60.9 | 1.8 |
| Larynx | 2679 | 92 | 23 | 59.8 | 3.5 |
| Lung, bronchus | 51 096 | 64 | 45 | 62.7 | 1.7 |
| Small-cell | 16 923 | 64 | 49 | 63.2 | 1.6 |
| Non–small-cell | 33 712 | 65 | 43 | 62.5 | 1.7 |
| Bones and joints | 955 | 28 | 39 | 38.3 | 6.4 |
| Melanoma of the skin | 1369 | 15 | 38 | 51.5 | 6.1 |
| Soft tissue (including heart) | 2268 | 60 | 44 | 48.1 | 5.2 |
| Female breast | 121 864 | 54 | 100 | 52.6 | 6.7 |
| Cervix | 4282 | 93 | 100 | 49.7 | 4.1 |
| Endometrium | 4683 | 52 | 100 | 61.3 | 3.8 |
| Ovary | 23 180 | 4 | 100 | 59.0 | 4.9 |
| Prostate | 3195 | 49 | 0 | 66.5 | 4.6 |
| Testis | 4418 | 8 | 0 | 32.8 | 11.4 |
| Urinary bladder | 9703 | 17 | 24 | 66.0 | 5.7 |
| Brain, central nervous system | 6241 | 94 | 40 | 48.6 | 2.8 |
| Hodgkin lymphoma | 10 976 | 39 | 43 | 39.6 | 8.6 |
| Non-Hodgkin lymphoma | 46 566 | 24 | 45 | 59.0 | 5.9 |
| Myeloma | 16 164 | 29 | 46 | 64.8 | 3.1 |
| First primary malignancy . | Total (N) . | Also received initial radiotherapy (%) . | Women (%) . | Mean age at diagnosis (y) . | Mean person-years at risk (y) . |
|---|---|---|---|---|---|
| Total* | 426 068 | 45 | 63 | 57.3 | 4.9 |
| Buccal cavity, pharynx | 9903 | 92 | 22 | 56.8 | 3.5 |
| Esophagus | 5535 | 88 | 23 | 63.1 | 2.2 |
| Stomach | 7707 | 50 | 32 | 61.3 | 2.4 |
| Colon | 38 064 | 8 | 49 | 62.5 | 4.5 |
| Rectum, rectosigmoid junction | 22 757 | 74 | 39 | 61.1 | 4.4 |
| Anus, anal canal, anorectum | 3476 | 96 | 62 | 58.6 | 5.4 |
| Biliary tract | 4015 | 36 | 41 | 60.9 | 1.8 |
| Larynx | 2679 | 92 | 23 | 59.8 | 3.5 |
| Lung, bronchus | 51 096 | 64 | 45 | 62.7 | 1.7 |
| Small-cell | 16 923 | 64 | 49 | 63.2 | 1.6 |
| Non–small-cell | 33 712 | 65 | 43 | 62.5 | 1.7 |
| Bones and joints | 955 | 28 | 39 | 38.3 | 6.4 |
| Melanoma of the skin | 1369 | 15 | 38 | 51.5 | 6.1 |
| Soft tissue (including heart) | 2268 | 60 | 44 | 48.1 | 5.2 |
| Female breast | 121 864 | 54 | 100 | 52.6 | 6.7 |
| Cervix | 4282 | 93 | 100 | 49.7 | 4.1 |
| Endometrium | 4683 | 52 | 100 | 61.3 | 3.8 |
| Ovary | 23 180 | 4 | 100 | 59.0 | 4.9 |
| Prostate | 3195 | 49 | 0 | 66.5 | 4.6 |
| Testis | 4418 | 8 | 0 | 32.8 | 11.4 |
| Urinary bladder | 9703 | 17 | 24 | 66.0 | 5.7 |
| Brain, central nervous system | 6241 | 94 | 40 | 48.6 | 2.8 |
| Hodgkin lymphoma | 10 976 | 39 | 43 | 39.6 | 8.6 |
| Non-Hodgkin lymphoma | 46 566 | 24 | 45 | 59.0 | 5.9 |
| Myeloma | 16 164 | 29 | 46 | 64.8 | 3.1 |
The study population was restricted to patients who were diagnosed with a first primary malignancy between ages 20 and 84 years and survived at least 1 year after diagnosis. Cohort follow-up was censored at age 85 years because of underascertainment of second malignancies among older patients.
All first primary malignancies excluding leukemia and nonmelanoma skin cancer. First primary malignancies after which <3 cases of tAML were observed among patients with initial chemotherapy were included in the “total” but are not presented separately in this table (eg, pancreas, kidney, thyroid).